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the absorption zone, leading to diminished efficacy of 
the administered dose.[1] To increase the gastric retention 
time of drugs, gastroretentive dosage forms (GRDF) can 
be developed.[2] These systems remain in the gastric region 
for several hours and can therefore significantly prolong 
the gastric residence time of the drugs. Prolonged gastric 
retention improves bioavailability, reduces drug waste, and 
improves solubility of drugs that are less soluble in the high 
pH environment of the small intestine.[3,4] It is quite difficult 
to achieve extensive retention of the GRDF, as the natural 
activity of the stomach is to evacuate its contents into the 
intestine. The main approaches that have been examined 
are low density GRDF that remains buoyant above the 
INTRODUCTION
Tablets are the most widely used dosage forms because 
of their convenience in terms of self-administration, 
compactness, and ease of manufacturing. However, 
oral administration has only a limited use for important 
drugs from various pharmacological categories that have 
poor oral bioavailability, due to incomplete absorption 
or degradation in the gastrointestinal (GI) tract. Some 
of these drugs are characterized by a narrow absorption 
window at the upper part of the gastrointestinal tract. 
Rapid and unpredictable gastrointestinal transit could 
result in incomplete drug release from the device above 
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The objective of this study was to evaluate the effect of formulation variables on the release properties, floating 
lag time, and hardness, when developing floating tablets of Ranitidine hydrochloride, by the statistical optimization 
technique. The formulations were prepared based on 32 factorial design, with polymer ratio (HPMC 100 KM: 
Xanthan gum) and the amount of aerosil, as two independent formulation variables. The four dependent (response) 
variables considered were: percentage of drug release at the first hour, T50% (time taken to release 50% of the 
drug), floating lag time, and hardness of the tablet. The release profile data was subjected to a curve fitting 
analysis, to describe the release mechanism of the drug from the floating tablet. An increase in drug release 
was observed with an increase in the polymer ratio, and as the amount of aerosil increased, the hardness of the 
tablet also increased, without causing any change in the floating lag time. The desirability function was used to 
optimize the response variables, each having a different target, and the observed responses were in accordance 
with the experimental values. The results demonstrate the feasibility of the model in the development of floating 
tablets containing Ranitidine hydrochloride.
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gastric fluid; high density, which retains the dosage form 
in the body of the stomach;[5] concomitant administration 
of drugs or excipients, which slow the motility of the 
gastrointestinal tract;[6] and bioadhesive or mucoadhesive 
dosage forms.[7] As most absorption windows are located in 
the proximal small intestine (duodenum), the most effective 
strategy to improve drug absorption will be to retain the 
formulation in the stomach.[8]
Ranitidine hydrochloride is a histamine H2-receptor 
antagonist. It is widely prescribed in active duodenal ulcers, 
gastric ulcers, Zollinger-Ellison syndrome, gastroesophageal 
reflux disease, and erosive esophagitis.[9] The effective 
treatment of erosive esophagitis requires administration 
of 150 mg of Ranitidine, four times a day. A conventional 
dose of 150 mg can inhibit gastric acid secretion up to five 
hours, but not up to 10 hours. An alternative dose of 300 
mg leads to plasma fluctuations; thus a sustained release 
dosage form of Ranitidine hydrochloride is desirable. The 
short biological half-life of the drug (~2.5 – 3 hours) also 
favors development of a sustained release formulation.
Ranitidine is absorbed only in the initial part of the small 
intestine and has 50% absolute bioavailability. Moreover, 
colonic metabolism of Ranitidine is partly responsible for 
the poor bioavailability of ranitidine from the colon.[10] The 
gastroretentive drug delivery systems can be retained in the 
stomach and assist in improving the oral sustained delivery 
of drugs that have an absorption window in a particular 
region of the gastrointestinal tract. These systems help 
in continuously releasing the drug before it reaches the 
absorption window, thus ensuring optimal bioavailability. 
The present study was aimed at developing floating tablets 
of Ranitidine hydrochloride, using the experimental design 
technique. A 32 full factorial design was used where the 
independent / formulation variables determined included 
a different ratio of polymers (HPMC: Xanthan Gum) and 
amount of aerosil, while the dependent / response variables 
determined were drug release in the first hour, time required 
for 50% of drug release,[11] floating lag time, and hardness 
of the tablet. A quadratic model was used to quantitatively 
evaluate the main effects and interaction. 
MATERIALS AND METHODS
Materials
Ranitidine Hydrochloride was received as a gift sample from 
Himanshu Pharmaceuticals and Embiotic Laboratories, 
Bangalore. Hydroxy propyl Methyl Cellulose (HPMC), citric 
acid, polyvinyl pyrrolidone (PVP), sodium bicarbonate, 
and colloidal silicon dioxide (Aerosil) were obtained as 
gift samples from Strides Arcolabs and Zydus Recon, 
Bangalore. Xantan gum and dicalcium phosphate were 
obtained as gift samples from Jagath Pharma, Bangalore. 
Magnesium stearate and talc were received as gift samples 
from Eros Pvt. Ltd., Bangalore.
Methods
Experimental design
In the present study, a 32 full factorial design containing 
two factors was evaluated at three levels [Table 1], and 
the experimental trials were performed in all possible 
combinations with three replicates of the center point.[12] 
The two independent formulation variables evaluated were:
X1: Different ratios of polymers (HPMC: Xanthan Gum) 
X2: Quantity of aerosil 
The response variables evaluated were:
Y1: Drug release at the first hour 
Y2: Time required for 50% of drug release (T 50%)
Y3: Floating lag time (in minutes)
Y4: Hardness of the tablet (in kg / cm2.)
Preparation of Ranitidine hydrochloride tablets (Preliminary 
trials)
Formulations were prepared according to the 32 factorial 
design [Table 2]. The ingredients were passed through a 
60 mesh sieve. The required quantities of HPMC, PVP, 
sodium bicarbonate, xantan gum, and dicalcium Phosphate 
were blended together in a suitable mixer. Ranitidine 
Hydrochloride was added to the above mixer in geometrical 
dilution and mixing was continued. Magnesium stearate, 
talc, and aerosil were finally added and the blend was then 
compressed into tablets using 12 mm flat-faced punches 
in a 10 station rotary tablet machine (Rimek RSB-4 Mini 
press Cadmach, Ahmedabad, India). 
EVALUATION OF TABLET PROPERTIES
Hardness 
The crushing strength of the tablets was measured using a 
Table 1: Selected factor levels for the experimental 
design used in the formulation of floating tablets
Model Actual values Coded values
Factor Low  Mid  High  Low Mid High
Factor A = HPMC: 
Xanthan Gum (X1)
0 : 180 90 : 90 180 : 0 - 1 0 + 1
Factor B = Aerosil (X2) 0 1.5 3.0 - 1 0 + 1Jain, et al. J Young Pharm. 2010;2(4): 342-349
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Pfizer hardness tester. Three tablets from each formulation 
batch were tested randomly and the average reading noted. 
The readings are given in Table 3.
Friability 
The friability of the tablet was determined using Roche 
Friabilator (Electrolab). Twenty previously weighed tablets 
were rotated at 25 rpm for four minutes. The weight loss of 
the tablets before and after measurement[13] was calculated 
using the following formula:
Percentage friability  =
Initial weight – Final weight
× 100
Initial weight
Weight variation 
The test was carried in conformity with the official method 
described in I.P (1996).[14] Twenty tablets from each batch 
were selected randomly after compression, weighed 
individually, and the average weight was determined. None 
of the tablets deviated from the average weight by more 
than 5%. 
Floating lag time 
A tablet was placed in a dissolution flask with 400 
ml of simulated gastric fluid maintained at 37 ± 1ºC. 
Subsequently, the time taken by tablet to move from the 
bottom to the top of the flask, in minutes, was measured.[15]
The readings are given in Table 3
Duration of buoyancy 
Duration of buoyancy was observed simultaneously when 
the dissolution studies were carried out. The time taken by 
the tablet to rise to the surface of the dissolution media 
and time taken for it to sink was noted, the difference of 
which gives the duration of buoyancy.[16]
Drug content
Ten tablets were randomly sampled from each formulation 
batch, finely powdered and individually estimated for 
the drug content after suitable dilution, using UV-VIS 
spectrophotometer (UV-1601, Shimadzu) at 313.5 nm.
In vitro drug release studies 
In vitro drug release studies for all the formulations were 
carried out using the tablet dissolution test apparatus (USP 
TDT 06PL, Electrolab, Mumbai). The dissolution medium 
used was simulated gastric fluid pH 1.2 (without enzymes) 
maintained at 37oC and the media was rotated at 50 rpm. 
Aliquots were withdrawn at 1-hour intervals for 12 hours, 
filtered and analyzed spectrophotometrically at 313.5 nm 
for cumulative drug release. The dissolution studies were 
conducted in triplicates and the mean values were plotted 
against time.
Data analysis 
To analyze the mechanism of drug release and release rate 
kinetics from the dosage form, the data obtained were fitted 
into zero order, first order, Higuchi release and Korsmeyer 
and Peppas release model using Prism and Sigma plot® 
software.[17]
Table 2: Composition of floating tablets of Ranitidine hydrochloride
Ingredients D 1 D 2 D 3 D 4 D 5 D 6 D 7 D 8 D 9 D 10 D 11
Ranitidine Hydrochloride 336 336 336 336 336 336 336 336 336 336 336
HPMC K-100 M 0 90 180 0 90 180 0 90 180 90 90
Xanthan gum 180 90 0 180 90 0 180 90 0 90 90
Aerosil 0 0 0 10 10 10 20 20 20 10 10
PVP K-30 60 60 60 60 60 60 60 60 60 60 60
Sodium bicarbonate 50 50 50 50 50 50 50 50 50 50 50
Dicalcium phosphate 30 30 30 30 30 30 30 30 30 30 30
Magnesium stearate 6 6 6 6 6 6 6 6 6 6 6
Talc 12 12 12 12 12 12 12 12 12 12 12
Total weight 674 674 674 684 684 684 694 694 694 684 684
*All the quantities expressed are in terms of milligrams
Table 3: Post-compression parameters for designed formulations
Parameters D1 D2  D3 D4 D5 D6 D7 D8 D9 D10 D11
Hardness (kg / cm2) 5.2 6.2 7.0 6.2 6.4 8.8 6.2 8.4 12.6 10.8 7.8
Floating Lag time (min) 1.70 4.39 2.58 1.77 0.81 1.08 1.20 1.19 0.42 1.02 0.82Floating dosage form of ranitidine hydrochloride
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Zero-order release kinetics
To study the zero-order release kinetics, the release rate 
data are fitted to the following equation:
F = Kt 
where, ‘F’ is the fraction of drug release, ‘K’ is the release 
rate constant and ‘t’ is the release time.
First–order release kinetics
To study the first-order release kinetics the release rate data 
are fitted to the following equation:
F = 100*(1 – e-Kt) 
Higuchi release model
To study the Higuchi release model the release rate data 
are fitted to the following equation:
F = Kt1/2 
Korsmeyer and Peppas release model
To study the Korsmeyer and Peppas release model the 
release rate data are fitted to the following equation:
Mt / M∞ = Ktn  
Where, Mt / M∞ is the fraction of drug release, ‘K’ is the 
release rate constant, ‘t’ is the release time and ‘n’ is the 
diffusional exponent for the drug release that is dependent 
on the shape of the matrix dosage form. 
Statistical analysis
The effect of formulation variables on the response 
variables were statically evaluated by applying one-way 
ANOVA at 0.05 level using a commercially available 
software package Design of Experiments® 6.05 (Stat Ease, 
USA). The design was evaluated by a quadratic model, 
which bears the form of the equation:
Y = b0 + b1 X1+ b2 X2 + b3 X1 X2 + b4 X1
2 + b5 X2 2 
Where Y is the response variable, b0 the constant, and b1, 
b2, b3…b5 is the regression coefficient. X1 and X2 stand for 
the main effect; X1X2 are the interaction terms, and show 
how response changes when two factors are simultaneously 
changed. X1
2, X2
2 are quadratic terms of the independent 
variables to evaluate the non-linearity. 
RESULTS AND DISCUSSION
The tablets were prepared following 32 full factorial 
design. For floating drug delivery system, the polymers 
used must be highly swellable in the shortest time. Hence, 
HPMC and Xantan gum were chosen as the main swellable 
polymers. HPMC was included in the formulation with the 
intention of adhering the dosage form to the inner wall 
of the stomach and also possibly to control the release 
of ranitidine from the dosage form. Hence, the effect of 
presence or absence of HPMC was considered as one of 
the independent factors. 
The rate of swelling of the polymer depends upon 
the amount of water taken up by the polymer. Hence 
sodium bicarbonate was added, which upon contact with 
hydrochloric acid liberated carbon-di-oxide (CO2) that 
escaped from the dosage form by creating pores, through 
which water could penetrate into the dosage form resulting 
in an increase in the rate of wetting of the polymer and a 
decrease in the time required for the same.
The hardness of all the formulations was in the range 
3.0 – 4.0 kg/cm2. The percentage friability of all the 
formulations was found to be not more than 0.6%. In all 
the formulations, the drug content was found to be uniform 
among the different batches of tablets, and ranged from 
98.38 to 102.49% of the theoretical value. The average 
percentage deviation for 20 tablets from each batch was 
within the acceptable pharmacopeial limits. 
The floating lag time for formulations containing HPMC and 
Xanthan gum was found to be between 3 and 30 minutes. 
Kinetic mechanism (curve fitting)
Fitting of the release data to the Krosmeyer and Peppas 
equation it was found that, the drug release rate at the first 
hour (%) ranged from 13.31 ± 0.5323 to 27.16 ± 1.087, the 
diffusion coefficient (n) ranged from 0.5167 ± 0.01913 to 
0.6752 ± 0.01744, and the T50% ranged from 3.179 to 6.188 
hours. These results indicated that the release mechanism 
was by diffusion and erosion. The diffusion coefficient 
values indicated that the drug release followed the non-
Fickian transport. The results are tabulated in Table 4.
The response dependent variables such as the drug release 
at the first hour, time required for 50% of drug release, 
floating lag time, and hardness were considered. These 
responses were subjected to multiple regression analyses 
of variance and the following observations were made.
Effect of formulation variables on release at the first 
hour
The model term for Ranitidine hydrochloride release at 
the first hour was found to be significant with a probability Jain, et al. J Young Pharm. 2010;2(4): 342-349
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Figure 1: Response surface plot showing the effect of (X1) and (X2) 
on the drug release at the first hour (Y1)
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Figure 2: Response surface plot showing the effect of (X1) and (X2) 
on time required for 50% of drug release (Y2)
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Table 4: Curve fitting data of release profile for designed formulations
Formulations D 1 D 2 D 3 D 4 D 5 D 6 D 7 D 8 D 9 D 10 D 11
Zero-order release kinetics
K (h-1) 7.442 8.707 9.904 6.371 7.592 9.831 7.215 8.173 9.549 8.715 8.477
SEM 0.4136 0.4198 0.5504 0.2459 0.3296 0.5679 0.2659 0.373 0.5753 0.4229 0.3715
R2 0.6563 0.7749 0.6926 0.873 0.8301 0.6363 0.8878 0.8043 0.5919 0.7651 0.8218
First order release kinetics
K (h-1) 0.1279 0.1686 0.2273 0.09621 0.1292 0.2251 0.1172 0.1483 0.2145 0.169 0.158
SEM 0.004828 0.005385 0.006834 0.002553 0.0037 0.00883 0.002911 0.004436 0.00482 0.006122 0.005753
R2 0.9466 0.9765 0.9857 0.9745 0.9761 0.9728 0.982 0.9766 0.9899 0.9689 0.9685
Krosmeyer and peppas 
model
K (h-n) 20.28 21.11 25.89 13.31 16.99 26.98 14.61 19.06 27.16 21.44 19.34
n 0.5365 0.5912 0.5563 0.6605 0.6285 0.5334 0.6752 0.6093 0.5167 0.5843 0.6195
SEM (K) 0.533 0.7371 1.476 0.5323 0.8222 1.37 0.5455 0.7258 1.087 0.5927 0.6797
SEM (n) 0.01252 0.0165 0.02707 0.01871 0.02274 0.02421 0.01744 0.01794 0.01913 0.01307 0.01654
T50% (hr) 5.378 4.3 3.264 7.418 5.571 3.179 6.188 4.869 3.258 4.26 4.634
R2 0.9964 0.9951 0.9854 0.995 0.9918 0.9867 0.9959 0.9945 0.9912 0.9968 0.9955
Higuchi model
K (h-1/2) 0.1279 0.1686 0.2273 0.09621 0.1292 0.2251 0.1172 0.1483 0.2145 0.169 0.158
SEM 0.004828 0.005385 0.006834 0.002553 0.0037 0.00883 0.002911 0.004436 0.00482 0.006122 0.005753
R2 0.9466 0.9765 0.9857 0.9745 0.9761 0.9728 0.982 0.9766 0.9899 0.9689 0.9685
value of 0.0278, indicating an adequate fitting to the surface 
linear model [Figure 1]. 
Y1 = 21.3070 + 3.3752 X1 – 0.3054 X2
In this model, factor X1, was found to be significant. As the 
ratio of polymers increased, the amount of drug release at 
the first hour had increased. Such a behavior of increase 
in the drug release at the first hour could 
be attributed to the formation of gel layer with low viscosity 
of the polymer matrix of HPMC alone, which in turn 
increased the influx of water into the gel matrix, leading 
to increased drug diffusion. In this model factor X2 was 
not found to be significant, as the concentration of aerosil 
did not influence any change in release at the first hour.
Effect of formulation variables on time required for 
50% of drug release
The model term for T50% was found to be highly significant 
with an F value of 0.0008 indicating the adequate fitting 
of the surface linear model [Figure 2]. As factor A was 
increased, the ‘T50%’ values were seen to decrease. However, 
the amount of aerosil did not show any significant effect 
on T50%. 
Y2 = 4.7562 - 1.5471 X1 + 0.2288 X2Floating dosage form of ranitidine hydrochloride
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Figure 3: Response surface plot showing the effect of (X1) and (X2) 
on Floating Lag Time (Y3)
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Figure 4: Response surface plot showing the effect of (X1) and (X2) 
on the hardness of tablets (Y4)
DESIGN-EXPERT Plot
Hardness
X = A: A
Y = B: B
5.50947  
7.1053  
8.70114  
10.297  
11.8928  
 
 
H
a
r
d
n
e
s
s
 
 
  -1.00
  -0.50
  0.00
  0.50
  1.00
0.00  
0.75  
1.50  
2.25  
3.00  
  A: A  
  B: B  
Effect of formulation variables on floating lag time
The model term for floating lag time was found to be very 
significant with the F value of 0.0167, indicating adequate 
fitting of the quadratic model. As the amount of aerosil in 
the dosage form increased, the floating lag time decreased, 
which may be due to the low density of aerosil and also 
due to the creation of void spaces in the tablet matrix. The 
factor X1 was found to be non-significant on the response 
floating lag time. The interaction factor X1 X2 could be 
studied with the help of response surface plot [Figure 3]. 
Y3 = 1.0502 - 0.0516 X1 - 0.6616 X2 – 0.0031 X1
2 + 0.5518 
X2
2 - 0.4162 X1 X2
Effect of formulation variables on hardness of the 
tablet
In this case, the model term for hardness of the tablet 
was found to be significant, with an F value 0.0135. Both 
the factors were significantly effective on the hardness of 
the tablet. As the polymer ratio increased it changed the 
polymer from Xantan gum to HPMC, and the hardness of 
a tablet increased. Similarly as the concentration of aerosil 
increased the hardness of the table also increased.
Y4 = 7.5636 + 1.825 X1 + 1.3666 X2 + 1.1375 X1 X2
The interaction factor X1 X2 can be studied with the help 
of the response surface plot [Figure 4].
The data of pure error and lack of fit are summarized in 
the ANOVA table [Table 5], which can provide a mean 
response and an estimate of pure experimental uncertainty. 
The residual values represent the differences between the 
observed and predicted values, given that the computed 
F values are respectively lesser than the critical F value, 
which denotes non-significance, with regard to lack of fit.
OPTIMIZATION 
A numerical optimization technique based on the 
desirability approach was used to generate the optimum 
settings for the most effective formulation with minimum 
floating lag time and time required for 50% of drug release. 
The optimized results obtained are included in Table 6. The 
results in Table 7 demonstrate a good relationship between 
the predicted and experimental values, confirming the 
practicability and validity of the model. The curve fitting 
data for optimized formulation is presented in Table 8. 
Furthermore, it is concluded that the mechanism of drug 
release from the Floating Drug Delivery System follows 
the non-fickian transport. The in vitro release profileof the 
optimized formulation is shown in Figure 5.
CONCLUSIONS
The present study was an attempt to formulate a 
gastroretentive floating drug delivery system of Ranitidine 
Hydrochloride, in order to improve its gastric residence 
time and bioavailability. A 32 full factorial design was 
performed to study the effect of formulation variables on 
drug release at the first hour, time required for 50% of 
drug release, floating lag time, and hardness of the tablets 
of Ranitidine Hydrochloride, by applying the optimization 
technique
The data from the release profile were fitted to various 
mathematical models, and fitting to the Korsmeyer and 
Peppas equation revealed that the release mechanism 
from the dosage form followed the non-fickian transport. Jain, et al. J Young Pharm. 2010;2(4): 342-349
348   Journal of Young Pharmacists Vol 2 / No 4
Table 5: Summary of ANOVA results in the analysis of 
lack of fit and pure error 
Source Sum of 
Squares
DF Mean 
Square
F Value Prob > F
Release at 1st hour
Model 68.91184 2 34.45592 5.798715 0.0278
X1 68.35211 1 68.35211 11.50323 0.0095
X2 0.559736 1 0.559736 0.0942 0.7667
Residual 47.53594 8 5.941993 - -
Lack of Fit 40.86556 6 6.810927 2.04214 0.3647
Pure Error 6.670381 2 3.33519 - -
Total 116.4478 10 - - -
Time required for  
50% of drug release
Model 14.67654 2 7.338268 19.90011 0.0008
X1 14.36235 1 14.36235 38.94819 0.0002
X2 0.314188 1 0.314188 0.852024 0.3830
Residual 2.950042 8 0.368755 - -
Lack of Fit 2.037853 6 0.339642 0.744675 0.6704
Pure Error 0.912189 2 0.456094 - -
Total 17.62658 10 - - -
Floating lag time
Model 4.163918 5 0.832784 8.653103 0.0167
X1 0.016017 1 0.016017 0.166422 0.7002
X2 2.626817 1 2.626817 27.29415 0.0034
X1
2 2.53E-05 1 2.53E-05 0.000262 0.9877
X2
2 0.771475 1 0.771475 8.016074 0.0366
X1 X2 0.693056 1 0.693056 7.201255 0.0436
Residual 0.481205 5 0.096241 - -
Lack of Fit 0.454488 3 0.151496 11.34095 0.0821
Pure Error 0.026717 2 0.013358 - -
Total 4.645123 10 - - -
Hardness 
Model 36.36604 3 12.12201 7.546334 0.0135
X1 19.98375 1 19.98375 12.44051 0.0096
X2 11.20667 1 11.20667 6.976502 0.0334
X1 X2 5.175625 1 5.175625 3.221989 0.1157
Residual 11.24441 7 1.606345 - -
Lack of Fit 3.004413 5 0.600883 0.145845 0.9631
Pure Error 8.24 2 4.12 - -
Total 47.61045 10 - - -
Table 6: Composition of the optimized formula
Ingredients Quantity (mg)
Ranitidine hydrochloride 336 
HPMC K-100 M 180
Aerosil 20
PVP K-30 60 
Sodium bicarbonate 50 
Dicalcium phosphate 30 
Magnesium stearate 6 
Talc 12 
Table 7: Comparison chart of the predicted and 
experimental values for optimized formulation
Dependent variables Optimized formulation
Predicted Experimental
Release at the first hour (%) 23.73 24.38
T 50% (hr) 3.96 3.43
Floating lag time (min) 0.55 0.47
Hardness (Kg/cm2) 12.2 11.83
Table 8: Curve fitting data for optimized formulation
Kinetic models Optimized formulation
Krosmeyer and peppas model
K (h-n) 23.730
n 0.569
SEM (K) 0.484
SEM (n) 0.010
R² 0.998
T 50% (hr) 3.963
Higuchi model
K(h –1/2) 27.320
SEM 0.292
R² 0.988
Zero order release kinetics
K(h –1) 9.335
SEM 0.478
R² 0.734
First order release kinetics
K(h -1) 0.1967
SEM 0.0067
R² 0.9768
Figure 5: In vitro release profile of the optimized formulation
0
10
20
30
40
50
60
70
80
90
100
110
1 2 3 4 5 6 7 8 9 10 11 12 13
%
C
D
R
Time (in hours)
Optimization by desirability function was performed to 
get the optimized formulae and the actual response values 
were in close agreement with the predicted values, thereby 
demonstrating the practicability and validity of the model. 
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